Life Science Connect

Considering many Life Science Leader readers daydream of starting and leading their own biopharmaceutical company someday, we thought it would be informative to host an executive virtual roundtable with three biopharmaceutical company CEOs who have done just that.

Diversity & inclusion is — and has been — an important issue for the biopharmaceutical industry. As such, we thought it would be worthwhile to gain some perspective.

Fundraising used to always be done in person. But then COVID hit. From those first virtual pitches that may have been just a little bit “wonky,” biopharma execs have actually become quite proficient at the process and the platforms. Three biopharma execs share some best practices of the virtual pitch.

According to Outsourced Pharma Chief Editor, Louis Garguilo, “politics has never played a bigger role in our (global) biopharma industry.” In this episode, we talk with Louis about three of his recent editorials that touch on this subject while also discussing the current IP debate in pharma and the origins of the coronavirus.

We thought it would be interesting to have a discussion with three biopharmaceutical executives about how they are preparing for this unique 2021 JPM and how those preparations are different than what they’ve done in the past.

We sat down with three biopharmaceutical industry executives to discuss some of the thinking and actions taken to mitigate risk to their companies’ manufacturing and supply chains amidst a pandemic.

Three biopharmaceutical industry VPs of HR departments discuss the challenges of continued operations amidst COVID-19 initiated lockdowns, along with some of the best practices implemented.

Erin Harris, chief editor of cellandgene.com explains what makes cell and gene therapy manufacturing more complex what some of the current hurdles and bottlenecks are that companies in this sector of life sciences face.

Pamela Contag, Ph.D., cofounder and CEO of BioEclipse Therapeutics, a clinical-stage oncology company; and Dara Lockert, founder and executive director of Spannerwerks, a life science industry consultancy, share best practices and lessons learned during the drive to get a biopharmaceutical startup to the clinic as quickly as possible.

Four biopharmaceutical industry CEOs and company cofounders converse on what their organizations are doing to spur the development of diagnostic tests, therapeutics, and vaccines in order to turn the tide on the COVID-19 pandemic.